Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- 1 October 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 385 (9965), 341-350
- https://doi.org/10.1016/s0140-6736(14)61374-x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial HypercholesterolemiaCirculation, 2012
- Low‐Density Lipoprotein Receptor Gene Familial Hypercholesterolemia Variant Database: Update and Pathological AssessmentAnnals of Human Genetics, 2012
- Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatmentAtherosclerosis, 2012
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering TherapyCirculation, 2011
- Recommendations for the use of LDL apheresisAtherosclerosis, 2008
- A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemiaAtherosclerosis, 2008
- Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial HypercholesterolemiaCirculation, 2002
- The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/DayThe American Journal of Cardiology, 1997
- Molecular genetics of the LDL receptor gene in familial hypercholesterolemiaHuman Mutation, 1992
- Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial HypercholesterolemiaThe New England Journal of Medicine, 1990